Search - tctmd.com

Displaying 1 - 20 of 211

Sort: Relevancy | Date

News Daily News

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Yael L. Maxwell

January 21, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Todd Neale

January 05, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Remission From Prediabetes Halves CV Risk: Registry Data

Yael L. Maxwell

December 19, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Michael O'Riordan

October 10, 2025

News Daily News

AI-Supported Coaching Shows Promise for Improving Glycemic Control

L.A. McKeown

August 25, 2025

News Daily News

Healthcare Expenses Increase After GLP-1 Prescription

L.A. McKeown

August 18, 2025

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Todd Neale

July 24, 2025

News Daily News

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Caitlin E. Cox

July 21, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Daily News

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

Caitlin E. Cox

June 25, 2025

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Michael O'Riordan

June 13, 2025

News Daily News

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

Todd Neale

June 06, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

Advertisement

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Year in Review: Top Prevention Stories of 2025

Remission From Prediabetes Halves CV Risk: Registry Data

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

AI-Supported Coaching Shows Promise for Improving Glycemic Control

Healthcare Expenses Increase After GLP-1 Prescription

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content